+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myelodysplastic Syndromes (MDS) in America 2023: Key Insights into Treatment Awareness & Satisfaction

  • Report

  • 43 Pages
  • April 2023
  • Region: Global
  • Health Union
  • ID: 5966539
This 43-page report provides a behind-the-scenes look at the treatment experience for those living with myelodysplastic syndromes (MDS). Using detailed quantitative data, it gives a full picture of the MDS treatment story - from HCP conversations to treatment awareness to use and satisfaction - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.

There are about 20,000 new cases of MDS each year in the United States. About 1 in 3 people with MDS develop acute myeloid leukemia (AML).

Myelodysplastic Syndromes (MDS) in America 2023: Key Insights into Treatment Awareness & Satisfaction offers a glimpse into the MDS treatment experience. It includes selected insights for stakeholders seeking a more focused view of patient perspectives on MDS treatment and satisfaction.

This large-scale, patient-reported data leverages vital quantitative insights essential to understanding HCP treatment discussions, treatment satisfaction and awareness, clinical trial interest, and much more.

What makes this report unique?

Very simply: the analyst's focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.

Valuable insights. Informed decisions.

This report lifts the curtain on the patient treatment experience, giving stakeholders an actionable look at the experiences of people living with the condition. Data can be used to inform strategic decisions, including competitive assessments, landscape analyses, patient journey overlays, and forecasting inputs.

This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost.

The analyst is a proven leader in understanding the experiences of people living with chronic health conditions. Through their portfolio of 45+ condition-specific online health communities, they reach millions of individuals, offering information, connection, and support to patients and caregivers in the U.S.

This report includes a deep-dive into:

  • HCP engagement
    • Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
  • MDS treatment awareness and experiences
    • Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials

Key questions answered in this report:

  • What percentage of patients see a specialist for MDS treatment?
  • What treatments have the highest aided brand awareness among patients?
  • What percentage of patients have used targeted therapy or immunotherapy?
  • How many patients feel their MDS is well-controlled on their current treatment plan?
  • What percentage of patients are likely to switch or add new treatments in the next six months?


  • The report consists of:
    • A 20-minute online quantitative survey

Additional details:

  • Fielded: January 16, 2023 to April 14, 2023
  • Convenience sample of 91 respondents diagnosed with MDS
  • Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners

Table of Contents


Respondent Demographic Highlights

Treatment Awareness and Experiences
  • Primary HCP Seen for MDS Care
  • Aided Brand Awareness of Treatments
  • Treatment Usage
  • Condition Control on Current Treatment
  • Clinical Trial Interest
Appendix with Associated Data Charts and Distributions

Products Mentioned

  • ARANESP® (darbepoetin alfa)
  • EPOGEN® (epoetin alfa)
  • GLEEVEC® (imatinib mesylate)
  • INQOVI® (decitabine and cedazuridine)
  • PROCRIT® (epoetin alfa)
  • REBLOZYL® (luspatercept-aamt)
  • REVLIMID® (lenalidomide)